Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02704403 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Phase 3 study, sponsored by Genfit.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,157
- Enrollment target
NCT02704403 is a Phase 3 study that was terminated before completion, run by Genfit. The registered enrollment target is 2,157 participants.
The verdict
NCT02704403, a Phase 3 study, was terminated before completion, sponsored by Genfit.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,157 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.
Interventions
- DRUG Placebo
- DRUG Elafibranor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,157 participants |
| Start Date | 2016-03 |
| Est. Completion | 2020-10-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02704403
The ClinicalTrials.gov registry entry for NCT02704403 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genfit, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02704403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02704403 about?
NCT02704403 is a clinical study titled "Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)". The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.
What is the current status of trial NCT02704403?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,157 participants. The study started on 2016-03. Estimated completion is 2020-10-28.
What interventions are being tested in trial NCT02704403?
The interventions under investigation include: Placebo (DRUG), Elafibranor (DRUG).
Who is sponsoring clinical trial NCT02704403?
This trial is sponsored by Genfit, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.